Citations

Showing 10 of 108094 citations.

High‐efficiency recombinant protein purification using mCherry and YFP nanobody affinity matrices
Cong, Anh , Witter, Taylor L. , Schellenberg, Matthew J. , Cong, Anh T Q

Mayo Clinic

Protein Science | August 26, 2022 | Volume: 31 | Issue: 9 | Pages: No page available

10.1002/pro.4383 | PMID 36040252 Get It

Abstract Mammalian cell lines are important expression systems for large proteins and protein complexes, particularly when the acquisition of post‐translational modifications in the protein's native environment is desired. However, low or variable transfection efficiencies are challenges that must be overcome to use such an expression system. Expression of recombinant proteins as a fluorescent protein fusion enables real‐time monitoring of protein expression, and also provides an affinity handle for one‐step protein purification using a suitable affinity reagent. Here, we describe a panel of anti‐GFP and anti‐mCherry nanobody affinity matrices and their efficacy for purification of GFP/YFP or mCherry fusion proteins. We define the molecular basis by which they bind their target proteins using X‐ray crystallography. From these analyses, we define an optimal pair of nanobodies for purification of recombinant protein tagged with GFP/YFP or mCherry, and demonstrate these nanobody‐sepharose supports are stable to many rounds of cleaning and extended incubation in denaturing conditions. Finally, we demonstrate the utility of the mCherry‐tag system by using it to purify recombinant human topoisomerase 2α expressed in HEK293F cells. The mCherry‐tag and GFP/YFP‐tag expression systems can be utilized for recombinant protein expression individually or in tandem for mammalian protein expression systems where real‐time monitoring of protein expression levels and a high‐efficiency purification step is needed.
A missense mutation in the proprotein convertase gene furinb causes hepatic cystogenesis during liver development in zebrafish
Ellis, Jillian L., Evason, Kimberley , Fourman, Makenzie N. , Liu, Jiandong , Delous, Marion , Fiddes, Ian T. , Otis, Jessica P. , Houvras, Yariv , Stainier, Didier Y. R. , Yin, Chunyue , Yin, Chunyue , Zhang, Changwen, Ninov, Nikolay , Vanhollebeke, Benoît , Farber, Steven , Xu, Xiaolei , Lin, Xueying

Mayo Clinic

Hepatology Communications | August 26, 2022 | Volume: 6 | Issue: 11 | Pages: 3083-3097

10.1002/hep4.2038 | PMID 36017776 Get It

Abstract Hepatic cysts are fluid‐filled lesions in the liver that are estimated to occur in 5% of the population. They may cause hepatomegaly and abdominal pain. Progression to secondary fibrosis, cirrhosis, or cholangiocarcinoma can lead to morbidity and mortality. Previous studies of patients and rodent models have associated hepatic cyst formation with increased proliferation and fluid secretion in cholangiocytes, which are partially due to impaired primary cilia. Congenital hepatic cysts are thought to originate from faulty bile duct development, but the underlying mechanisms are not fully understood. In a forward genetic screen, we identified a zebrafish mutant that developed hepatic cysts during larval stages. The cyst formation was not due to changes in biliary cell proliferation, bile secretion, or impairment of primary cilia. Instead, time‐lapse live imaging data showed that the mutant biliary cells failed to form interconnecting bile ducts because of defects in motility and protrusive activity. Accordingly, immunostaining revealed a disorganized actin and microtubule cytoskeleton in the mutant biliary cells. By whole‐genome sequencing, we determined that the cystic phenotype in the mutant was caused by a missense mutation in the furinb gene, which encodes a proprotein convertase. The mutation altered Furinb localization and caused endoplasmic reticulum (ER) stress. The cystic phenotype could be suppressed by treatment with the ER stress inhibitor 4‐phenylbutyric acid and exacerbated by treatment with the ER stress inducer tunicamycin. The mutant liver also exhibited increased mammalian target of rapamycin (mTOR) signaling. Treatment with mTOR inhibitors halted cyst formation at least partially through reducing ER stress. Conclusion : Our study has established a vertebrate model for studying hepatic cystogenesis and illustrated the contribution of ER stress in the disease pathogenesis.
Classical and non‐classical phenotypes of Erdheim–Chester disease: Correlating clinical, radiographic and genotypic findings
Hazim, Antonious , Acosta‐Medina, Aldo A. , Ruan, Gordon , Abeykoon, Jithma P. , Ravindran, Aishwarya , Vassallo, Robert , Ryu, Jay H. , Tobin, W. Oliver , Hazim, Antonious Z , Ruan, Gordon J , Abeykoon, Jithma P , Ravindran, Aishwarya , Shah, Mithun V , Goyal, Guarav , Tobin, W Oliver , Vassallo, Robert , Ryu, Jay H , Acosta-Medina, Aldo A , Young, Jason R. , Koster, Matthew J. , Bennani, N. Nora , Rech, Karen L. , Shah, Meera , Witzig, Thomas E. , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

British Journal of Haematology | August 26, 2022 | Volume: 199 | Issue: 3 | Pages: 454-457

10.1111/bjh.18422 | PMID 36017680 Get It

Urinary Outcomes After Magnetic Resonance Imaging-Guided Whole-Gland Transurethral Ultrasound Ablation for Prostate Cancer: Comparison of Suprapubic Tube to Indwelling Urethral Catheter
Myers, Amanda A. , Dora, Chandler , Dora, Chandler D , Myers, Amanda , Rabinowitz, Matthew J., Haney, Nora M. , Pavlovich, Christian P.

Mayo Clinic

Journal of Endourology | August 26, 2022 | Volume: 37 | Issue: 1 | Pages: 1-7

10.1089/end.2022.0214 | PMID 36017622 Get It

Background: MRI-guided transurethral ultrasound ablation (TULSA) is under investigation for whole-gland ablation of low- and intermediate-risk prostate cancer. The ideal method for post-TULSA bladder drainage through postoperative suprapubic tube (SPT) vs indwelling urethral catheter (UC) has not been established. The objective of this study was to evaluate urinary outcomes after whole-gland TULSA, comparing postoperative SPT with UC. Materials and Methods: Two-institution retrospective analysis of whole-gland TULSA for men with grade group 1 and 2 prostate cancer. One institution placed SPT at the time of TULSA with clamp trials (day 10) and removal once voiding. The second placed UC until void trial (day 7). Outcomes included the International Prostate Symptom Score (IPSS), urinary bother score, catheter reinsertion, stricture, clean intermittent catheterization (CIC), and incontinence. Results: Forty-five patients (median age 67) were analyzed. The UC cohort ( N = 26) was older ( p = 0.007) than the SPT cohort ( N = 19) but with similar baseline prostate volumes, IPSS, and urinary bother scores. Patients receiving UC had fewer days with catheter ( p = 0.013). Although UC patients suffered more lower urinary tract symptoms at 1-month post-TULSA, there was no significant difference between IPSS scores at baseline and 6 months after surgery regardless of urinary management strategy, although the UC group noted significantly decreased urinary bother. Rates of infection were similar between groups. Six strictures were observed overall, with more in the SPT group, although the difference was not significant (4/19 [21.1%] SPT; 2/26 [7.7%] UC). At 6 months, incontinence rates were low and similar between groups (2/19 [10.5%] SPT; 4/26 [15.4%] UC) and only one patient (UC) required CIC. Conclusions: Our overall findings suggest that SPT and UC are both acceptable options for postoperative bladder drainage after whole-gland TULSA, with statistically similar rates of urinary complications but a slightly different side effect profile.
Diaphragm preservation during combined abdominal and cardiothoracic deceased donor procurements
Mohamed, Mohamed I. , Markuson, Heather , Toone, Holly M., Sonnenwald, Sherry L., Dougherty, Marjorie K., Musto, Kaitlyn R., Harnois, Denise M. , Nguyen, Justin H.

Mayo Clinic

Liver Transplantation | August 26, 2022 | Volume: 29 | Issue: 3 | Pages: 343-345

10.1002/lt.26566 | PMID 36017609 Get It

Suppurative Thrombosis of the Portal Vein (Pylephlebits): A Systematic Review of Literature
Jevtic, Dorde , Gavrancic, Tatjana , Pantić, Ivana , Nordin, Terri , Nordstrom, Charles W. , Antic, Marina , Pantić, Nikola , Kaljevic, Marija , Joksimović, Bojan , Jovanović, Milan , Petcu, Emilia, Jecmenica, Mladen , Milovanovic, Tamara, Sprecher, Lawrence J., Dumic, Igor , Alempijević, Tamara , Sprecher, Lawrence, Alempijevic, Tamara , Dumic, Igor , Jevtic, Djordje , Joksimović, Bojan

Mayo Clinic

Journal of Clinical Medicine | August 26, 2022 | Volume: 11 | Issue: 17 | Pages: 4992

10.3390/jcm11174992 | PMID 36078922 Get It

Suppurative portal vein thrombosis (pylephlebitis) is an uncommon condition usually associated with an intra-abdominal infection or inflammatory process. In this study, we aimed to synthesize data on previously published cases according to the PRISMA guidelines. A total of 103 patients were included. Patients were more commonly male (71.8%) and had a mean age of 49 years. The most common infection associated with pylephlebitis was diverticulitis (n = 29, 28.2%), and Escherichia coli was the most isolated pathogen (n = 21, 20.4%). Blood cultures were positive in 64 cases (62.1%). The most common site of thrombosis was the main portal vein (PV) in 59 patients (57.3%), followed by the superior mesenteric vein (SMV) in 40 patients (38.8%) and the right branch of the PV in 30 patients (29.1%). Sepsis developed in 60 patients (58.3%). The mortality rate in our review was 8.7%, and independent risk factors for mortality were the presence of pertinent comorbidities (OR 5.5, p = 0.02), positive blood cultures (OR 2.2, p = 0.02), and sepsis (OR 17.2, p = 0.049).
Glutamate Neurotoxicity and Destruction of the Blood–Brain Barrier: Key Pathways for the Development of Neuropsychiatric Consequences of TBI and Their Potential Treatment Strategies
Gruenbaum, Benjamin F. , Frenkel, Amit , Boyko, Matthew , Frenkel, Amit , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich , Fleidervish, Ilya A.

Mayo Clinic

International Journal of Molecular Sciences | August 25, 2022 | Volume: 23 | Issue: 17 | Pages: 9628

10.3390/ijms23179628 | PMID 36077024 Get It

Traumatic brain injury (TBI) is associated with significant cognitive and psychiatric conditions. Neuropsychiatric symptoms can persist for years following brain injury, causing major disruptions in patients’ lives. In this review, we examine the role of glutamate as an aftereffect of TBI that contributes to the development of neuropsychiatric conditions. We hypothesize that TBI causes long-term blood–brain barrier (BBB) dysfunction lasting many years and even decades. We propose that dysfunction in the BBB is the central factor that modulates increased glutamate after TBI and ultimately leads to neurodegenerative processes and subsequent manifestation of neuropsychiatric conditions. Here, we have identified factors that determine the upper and lower levels of glutamate concentration in the brain after TBI. Furthermore, we consider treatments of disruptions to BBB integrity, including repairing the BBB and controlling excess glutamate, as potential therapeutic modalities for the treatment of acute and chronic neuropsychiatric conditions and symptoms. By specifically focusing on the BBB, we hypothesize that restoring BBB integrity will alleviate neurotoxicity and related neurological sequelae.
Risk of Cardiovascular Implantable Electronic Device Infection in Patients Presenting With Gram-Negative Bacteremia
Chesdachai, Supavit , Baddour, Larry M. , Sohail, M. Rizwan , Palraj, Bharath Raj, Madhavan, Malini , Tabaja, Hussam , Lahr, Brian D. , DeSimone, Daniel C. , Palraj, Raj , DeSimone, Daniel C , Baddour, Larry , Sohail, M Rizwan , Palraj, Raj , Chesdachai, Supavit , Tabaja, Hussam , Fida, Madiha

Mayo Clinic

Open Forum Infectious Diseases | August 25, 2022 | Volume: 9 | Issue: 9 | Pages: No page available

10.1093/ofid/ofac444 | PMID 36092830 Get It

Abstract Background Gram-negative bacteremia (GNB) as a manifestation of cardiovascular implantable electronic device (CIED) infection is uncommon. Moreover, echocardiography may be nonspecific in its ability to differentiate whether CIED lead masses are infected. We aimed to determine the rate of CIED infection in the setting of GNB. Methods All patients with CIED who were hospitalized with GNB during 2012–2019 at Mayo Clinic were investigated. The definition of CIED infection was based on criteria recommended by the 2019 European Heart Rhythm Association document. Results A total of 126 patients with CIED developed GNB. None of them had signs of pocket infection. Twenty (15.9%) patients underwent transesophageal echocardiography. Overall, 4 (3%) patients had definite CIED infection. None of them underwent CIED extraction; 3 died within 12 weeks and 1 received long-term antibiotic suppression. Ten (8%) patients had possible CIED infection; despite no CIED extraction, no patient had relapsing GNB. We observed a higher rate of CIED infection in patients with Serratia marcescens bacteremia as compared to that in patients with other GNB. Conclusions The rate of CIED infection following GNB was relatively low. However, accurate classification of CIED infection among patients presenting with GNB remains challenging, in part, due to a case definition of CIED infection that is characterized by a low pretest probability in the setting of GNB. Prospective, multicenter studies are needed to determine accurate identification of CIED infection among GNB, so that only patients with true infection undergo device removal.
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer
Yoon, Harry H. , Jin, Zhaohui , Kour, Oudom, Fonkoua, Lionel Aurelien Kankeu , Shitara, Kohei , Moehler, Markus, Shi, Qian , Kankeu Fonkoua, Lionel Aurelien, Shi, Qian , Jin, Zhaohui , Gibson, Michael K. , Prokop, Larry J. , Kang, Yoon‐Koo , Ajani, Jaffer A.

Mayo Clinic

JAMA Oncology | August 25, 2022 | Volume: 8 | Issue: 10 | Pages: 1456

10.1001/jamaoncol.2022.3707 | PMID 36006624 Get It

ImportanceApproval by the US Food and Drug Administration of immune checkpoint inhibition (ICI) for advanced gastroesophageal cancer (aGEC) irrespective of PD-L1 status has generated controversy. Exploratory analyses from individual trials indicate a lack of meaningful benefit from ICI in patients with absent or low PD-L1 expression; however, analysis of a single variable while ignoring others may not consider the instability inherent in exploratory analyses.ObjectiveTo systematically examine the predictive value of tissue-based PD-L1 status compared with that of other variables for ICI benefit in aGEC to assess its stability.Data SourcesMEDLINE, Embase, Scopus, Web of Science, Cochrane Central Register (2000-2022).Study Selection, Data Extraction, and SynthesisRandomized clinical trials (RCTs) were included of adults with aGEC (adenocarcinoma [AC] or squamous cell carcinoma [SCC]) randomized to anti−PD-1 or PD-L1−containing treatment vs standard of care (SOC). Study screening, data abstraction, and bias assessment were completed independently by 2 reviewers. Of 5752 records screened, 26 were assessed for eligibility; 17 trials were included in the analysis.Main Outcomes and MeasuresThe prespecified primary end point was overall survival. The mean hazard ratio (HR) for ICI vs SOC was calculated (random-effects model). Predictive values were quantified by calculating the ratio of mean HRs between 2 levels of each variable.ResultsIn all, 17 RCTs (9 first line, 8 after first line) at low risk of bias and 14 predictive variables were included, totaling 11 166 participants (5067 with SCC, 6099 with ACC; 77.6% were male and 22.4% were female; 59.5% of patients were younger than 65 years, 40.5% were 65 years or older). Among patients with SCCs, PD-L1 tumor proportion score (TPS) was the strongest predictor of ICI benefit (HR, 0.60 [95% CI, 0.53-0.68] for high TPS; and HR, 0.84 [95% CI, 0.75-0.95] for low TPS), yielding a predictive value of 41.0% favoring high TPS (vs ≤16.0% for other variables). Among patients with AC, PD-L1 combined positive score (CPS) was the strongest predictor (after microsatellite instability high status) of ICI benefit (HR, 0.73 [95% CI, 0.66-0.81] for high CPS; and HR, 0.95 [95% CI, 0.84-1.07] for low CPS), yielding a predictive value of 29.4% favoring CPS-high (vs ≤12.9% for other variables). Head-to-head analyses of trials containing both levels of a variable and/or having similar design generally yielded consistent results.Conclusions and RelevanceTissue-based PD-L1 expression, more than any variable other than microsatellite instability-high, identified varying degrees of benefit from ICI-containing therapy vs SOC among patients with aGEC in 17 RCTs.
Reporting of Race and Hispanic Ethnicity in Breast Cancer Studies From the National Cancer Database
Bazan, Jose G. , Gamez, Mauricio E. , Obeng‐Gyasi, Samilia

Mayo Clinic

JAMA Oncology | August 25, 2022 | Volume: 8 | Issue: 10 | Pages: 1507

10.1001/jamaoncol.2022.3527 | PMID 36006628 Get It

This cohort study characterizes the inclusion of Hispanic ethnicity or ethnoracial categories in breast cancer studies from the National Cancer Database.